Measures to prevent the development of drug resistance in patients with tuberculosis at the ambulatory stage of treatment

In 2018, at the WHO assembly, tuberculosis was recognized as a disease that claims a large number of human lives. One of the important factors in the ineffectiveness of treatment is the identification of extensive destructive processes with bacterial excretion, which often leads to the development of drug resistance. So, according to Mysticova N.G. (2019) the WHO European Region has the highest incidence of multidrug-resistant rifampicin-resistant tuberculosis (MDR / RR-TB) at 14 cases per 100,000 population. Numerous studies of domestic and foreign authors are devoted to the issue of drug resistance of mycobacterium tuberculosis. In the Republic of Uzbekistan, one of the urgent problems of phthisiology is the increase in the number of drug-resistant tuberculosis.